Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study
The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with chemotherapy for never smoker patients with advanced non-small cell lung cancer (N
Lantern Pharma Receives FDA Authorization To Initiate Its Phase 2 Clinical Trial, Harmonic, For LP-300 In Never Smokers With Non-Small Cell Lung Cancer
The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022.
In a previous Phase 3
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Lantern Pharma Announces Extension Of Existing Share Repurchase Program
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children’s Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio
DALLAS, Feb. 15, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to
Benzinga Announces This Week’s All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, presented by RedChip, set to air Friday, January 28 at 9:15 am ET.
The Lineup
9:15 am: Opening Remarks with RedChip
